SEC Form 4 · accession 0001179022-15-000084
GALECTIN THERAPEUTICS INC · GALT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Steven Prelack
Director
Period of report
Mar 12, 2015
Accepted (ET)
Jul 8, 2015 · 4:58 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001133416
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Mar 12, 2015 | A | 11,112 | $0.00 | A | 14,048 | D | |
| Common Stock | Apr 8, 2015 | A | 2,259 | $0.00 | A | 16,307 | D | |
| Common Stock | Apr 8, 2015 | A | 90,882 | $0.00 | A | 107,189 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F2,F1 | $7.08 | Apr 8, 2015 | D | 6,168 | D | — | Jun 28, 2021 | Common Stock | 6,168 | 0 | D |
| Stock Option (right to buy)F2,F3 | $3.59 | Apr 8, 2015 | D | 16,714 | D | — | Mar 28, 2023 | Common Stock | 16,714 | 0 | D |
Explanation of responses
- F1The option vested as to one-eighth of the shares on June 28, 2011 and thereafter quarterly in seven equal installments beginning August 12, 2011.
- F2The option was canceled by mutual agreement of the reporting person and Galectin Therapeutics, Inc. The reporting person received 19,504 shares of restricted common stock, reported in Table 1 of this Form 4 as a part of the April 8, 2015 grant of 90,882 shares, as consideration for the cancellation of options granted on June 28, 2011 and March 28, 2013.
- F3The option vested quarterly in eight equal installments beginning on May 12, 2013.